CalciMedica Inc., a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, announced a collaboration with Telperian, a clinical trial intelligence company, to integrate Telperian’s artificial intelligence (AI) engine into the analysis of clinical trial data for Auxora, CalciMedica’s lead compound.
Partnership Focus
The collaboration will leverage Telperian’s AI, biostatistics, and domain expertise to analyze data from completed Auxora clinical trials, including:
- Phase 2b CARPO trial in patients with acute pancreatitis (AP) and systemic inflammatory response syndrome (SIRS)
- Phase 2 CARDEA trial in patients with severe COVID-19 pneumonia
Additionally, Telperian will use its platform to emulate historical critical care studies and identify patterns that may guide the design of a pivotal trial for Auxora. Insights gained will support CalciMedica’s regulatory discussions with the US Food and Drug Administration (FDA).
About Auxora
Auxora is a potent and selective small molecule CRAC channel inhibitor under development for acute inflammatory and immunologic illnesses. Its potential therapeutic applications include:
- Acute pancreatitis (AP)
- Severe COVID-19 pneumonia
- Acute kidney injury (AKI) with respiratory failure – currently being evaluated in the phase 2 KOURAGE trial, with data expected in early 2026
Rachel Leheny, Ph.D., CEO of CalciMedica, said:
"CARPO and CARDEA are two critical trials contributing to the strong body of evidence supporting Auxora as a potentially transformative treatment. Telperian’s advanced AI engine will allow us to refine our understanding of treatment effects across patient subgroups and enhance the design of our pivotal AP program."
Role of Telperian’s AI Platform
Telperian’s platform offers:
- Asynchronous review of statistical data in regulatory submissions
- Historical evidence-based design intelligence
- Novel patient subtyping methodologies
- Comprehensive study design expertise
Rick Landin, co-founder and CEO of Telperian, commented:
"Our AI tools will accelerate detailed insights into Auxora’s pharmacokinetics and therapeutic effects. This collaboration highlights the potential of AI to streamline clinical development and regulatory processes."
About the Companies
CalciMedica Inc. focuses on CRAC channel inhibition therapies to modulate immune responses and protect tissue cells from injury, aiming to address life-threatening inflammatory and immunologic diseases that currently lack approved treatments.
Telperian provides Statistical Lifecycle solutions for drug developers, automating and optimizing clinical trial design, data analysis, and regulatory submissions to reduce errors, costs, and delays.
